Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

AbstractAim:To investigate the pharmacodynamics and pharmacokinetics of gemcitabine (dFdC) administered on d 1 and 5 plus cisplatin administered on d 1 in chemonaive patients with stage IIIB or IV non-small cell lung cancer (NSCLC).Methods:In each combination cycle, gemcitabine was administered at a dose of 1250 mg/m2 as a 30 min intravenous (iv) infusion on d 1 and 5 followed by cisplatin at a dose of 75 mg/m2 as a 3 h iv infusion on d 1 every 3 weeks. There was an interval of 1 h between the two infusions. Clinical response and toxicity of the regimen were observed. Furthermore, the plasma concentrations of gemcitabine (dFdC) and its metabolite (dFdU) at different time points were detected during the first cycle of infusion. Pharmacokinetic software (PKS) was used to estimate the pharmacokinetic parameters of gemcitabine and its metabolite dFdU.Results:A total of 28 patients was enrolled in the study. The median age was 54 years (range 27–75 years), and most patients were in good clinical condition. Twenty-seven patients received two or more treatment cycles. The overall clinical response rate was 33.3%. The median overall survival time was 13 months. The estimated median time to tumor progression (TTP) was 6.2 months, and the 1-year survival rate was 55.6%. Toxicities were tolerated. The main toxicity was myelosuppression; 35.7% of patients had grade 3/4 hematologic toxicities and 28.6% had grade 3/4 non-hematologic toxicities, which were commonly gastrointestinal responses. The pharmacokinetic parameters of dFdC and dFdU were not different between pre- and post-administration of gemcitabine on d 1 and 5. dFdU was minimal (0.729±0.637 μg/mL) before gemcitabine was infused on d 5, and gemcitabine was not present.Conclusion:The regimen is active and well tolerated in chemonaive patients with advanced NSCLC. After gemcitabine was administered on d 1 and 5, the pharmacokinetic parameters of dFdC and dFdU showed no difference from those before the infusion, and dFdU was minimal before gemcitabine was administered on d 5.

[1]  Jos H. Beijnen,et al.  New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine , 2008, Molecular Cancer Therapeutics.

[2]  J. Ahn,et al.  A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer. , 2006, Lung cancer.

[3]  M. Ducreux,et al.  A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. , 2000, European journal of cancer.

[4]  G. Peters,et al.  Schedule-dependent antitumor effect of gemcitabine in in vivo model system. , 1995, Seminars in oncology.

[5]  Y F Hui,et al.  Gemcitabine: a cytidine analogue active against solid tumors. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[6]  G. Peters,et al.  Synergistic interaction between cisplatin and gemcitabine in vitro. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Peters,et al.  Interaction between cisplatin and gemcitabine in vitro and in vivo. , 1995, Seminars in oncology.

[8]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[9]  O. Ozyılkan,et al.  Gemcitabine and Cisplatin Treatment of Advanced-Stage Non-Small-Cell Lung Cancer in Patients Given Cisplatin on Day 8 , 2008, Tumori.

[10]  Jeffrey M Trent,et al.  Adrenocortical carcinoma survival rates correlated to genomic copy number variants , 2008, Molecular Cancer Therapeutics.

[11]  K. Roszkowski,et al.  A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. , 2002, Lung cancer.

[12]  H. Groen,et al.  A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  F. Koşar,et al.  Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study. , 2007, Lung cancer.

[15]  M. Alloisio,et al.  Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: Result of a dose-intensity study , 2006, Investigational New Drugs.

[16]  S. Allerheiligen,et al.  Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.

[17]  G. López-Vivanco,et al.  Biweekly Administration of Cisplatin/Gemcitabine in Advanced Nonsmall Cell Lung Cancer , 2005, American journal of clinical oncology.

[18]  C. Belani.  Chemotherapy Regimens in Advanced Non-Small-Cell Lung Cancer: Implications and Future Perspectives , 2000 .

[19]  F. Shepherd,et al.  Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. , 1997, Seminars in oncology.

[20]  C. Belani.  Chemotherapy regimens in advanced non-small-cell lung cancer: recent randomized trials. , 2002, Clinical lung cancer.

[21]  G. Peters,et al.  Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Giaccone,et al.  Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Schellens,et al.  Extensive Metabolism and Hepatic Accumulation of Gemcitabine After Multiple Oral and Intravenous Administration in Mice , 2008, Drug Metabolism and Disposition.

[24]  Z. Wen-zhao,et al.  Efficacy of Gemcitabine Plus Platinum Chemotherapy Compared with Other Platinum Containing Regimens in Advanced Non-small-cell Lung Cancer:A Meta-analysis of Survival Outcomes , 2005 .

[25]  G. Peters,et al.  No evidence of gemcitabine accumulation during weekly administration , 2005, European Journal of Clinical Pharmacology.

[26]  S. Zeng,et al.  Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector. , 2004, Acta pharmacologica Sinica.

[27]  J. Xiong,et al.  Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer. , 2008, Lung cancer.

[28]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.